![Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | ATRA Stock News Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | ATRA Stock News](https://static.stocktitan.net/company-logo/ATRA-lg.png)
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | ATRA Stock News
![Pierre Fabre : le CHMP recommande l'approbation d'Ebvallo d'Atara Biotherapeutics | MyPharma Editions Pierre Fabre : le CHMP recommande l'approbation d'Ebvallo d'Atara Biotherapeutics | MyPharma Editions](https://www.mypharma-editions.com/wordpress/wp-content/uploads/2022/10/2022-10-14_133833.jpg)
Pierre Fabre : le CHMP recommande l'approbation d'Ebvallo d'Atara Biotherapeutics | MyPharma Editions
![Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | Business Wire Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | Business Wire](https://mms.businesswire.com/media/20231220458866/en/1976254/23/Atara-Bio1_R_whtbox_3000px20190319.jpg)
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | Business Wire
![Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results | Business Wire Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results | Business Wire](https://mms.businesswire.com/media/20231031702630/en/792504/23/Atara-Bio1_logo_300x185-1.jpg)
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results | Business Wire
![Fenwick on X: "Congrats to Atara Biotherapeutics, Inc (Nasdaq: ATRA) in its expanded partnership with Pierre Fabre Laboratories for the U.S. & remaining global commercial markets for tab-cel for up to $640 Fenwick on X: "Congrats to Atara Biotherapeutics, Inc (Nasdaq: ATRA) in its expanded partnership with Pierre Fabre Laboratories for the U.S. & remaining global commercial markets for tab-cel for up to $640](https://pbs.twimg.com/tweet_video_thumb/F94GNuZWMAAxIDC.jpg)
Fenwick on X: "Congrats to Atara Biotherapeutics, Inc (Nasdaq: ATRA) in its expanded partnership with Pierre Fabre Laboratories for the U.S. & remaining global commercial markets for tab-cel for up to $640
![Pierre Fabre va commercialiser et distribuer la première immunothérapie allogénique à lymphocytes T en Europe suite au transfert de l'autorisation de mise sur le marché accordée par la Commission européenne pour EBVALLO® ( Pierre Fabre va commercialiser et distribuer la première immunothérapie allogénique à lymphocytes T en Europe suite au transfert de l'autorisation de mise sur le marché accordée par la Commission européenne pour EBVALLO® (](https://mma.prnewswire.com/media/1970795/Pierre_Fabre_Atara_Logo.jpg?p=facebook)
Pierre Fabre va commercialiser et distribuer la première immunothérapie allogénique à lymphocytes T en Europe suite au transfert de l'autorisation de mise sur le marché accordée par la Commission européenne pour EBVALLO® (
![Atara Biotherapeutics Expands its Collaboration Agreement with Laboratoires Pierre Fabre to Develop and Commercialize Ebvallo Globally Atara Biotherapeutics Expands its Collaboration Agreement with Laboratoires Pierre Fabre to Develop and Commercialize Ebvallo Globally](https://pharmashots.com/public/images/20221220185253_original_35.webp)
Atara Biotherapeutics Expands its Collaboration Agreement with Laboratoires Pierre Fabre to Develop and Commercialize Ebvallo Globally
![Atara Biotherapeutics Inc.: Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress - Form 8-K - MoneyController (ID 1539617) Atara Biotherapeutics Inc.: Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress - Form 8-K - MoneyController (ID 1539617)](https://www.moneycontroller.fr/upload/aziende/atara-biotherapeutics-inc_20210427131418.png)
Atara Biotherapeutics Inc.: Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress - Form 8-K - MoneyController (ID 1539617)
Pierre Fabre; Atara: CHMP Recommends Approval of Atara Biotherapeutics' EbvalloTM (tabelecleucel) for the Treatment of Epstein-B
![Atara Biotherapeutics announces closing of expanded global Tab Cel partnership with Pierre Fabre Labs - Medical Update Online Atara Biotherapeutics announces closing of expanded global Tab Cel partnership with Pierre Fabre Labs - Medical Update Online](https://medicalupdateonline.com/wp-content/uploads/2023/12/AdobeStock_366674524_Editorial_Use_Only.jpg)
Atara Biotherapeutics announces closing of expanded global Tab Cel partnership with Pierre Fabre Labs - Medical Update Online
![EMA to review Atara's MAA submission for allogeneic T-cell therapy: 'A watershed moment for the field' EMA to review Atara's MAA submission for allogeneic T-cell therapy: 'A watershed moment for the field'](https://www.biopharma-reporter.com/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_large/publications/pharmaceutical-science/biopharma-reporter.com/article/2021/11/30/ema-to-review-atara-s-maa-submission-for-allogeneic-t-cell-therapy-a-watershed-moment-for-the-field/13052871-1-eng-GB/EMA-to-review-Atara-s-MAA-submission-for-allogeneic-T-cell-therapy-A-watershed-moment-for-the-field.jpg)
EMA to review Atara's MAA submission for allogeneic T-cell therapy: 'A watershed moment for the field'
![Em negócio de até US$ 640 milhões, Pierre Fabre dobra sua parceria de células T com Atara - Guia da Farmácia Em negócio de até US$ 640 milhões, Pierre Fabre dobra sua parceria de células T com Atara - Guia da Farmácia](https://guiadafarmacia.com.br/wp-content/uploads/2023/11/Pierre-Fabre-nova-sede-1.jpg)